uniQure: AMT-130 BLA accepted for priority review
uniQure's AMT-130 BLA was accepted with priority review, an FDA advisory committee is expected, and a roughly 200-patient confirmatory study is in preparation.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
uniQure's BLA for AMT-130 was accepted by the FDA with priority review, according to TradingView. An FDA advisory committee is expected. The company is also preparing a global confirmatory study of about 200 patients.
Management cited durable TFC results. Ahead, uniQure expects UK review, pipeline updates in H1 2027, and cash runway into 2030.
why it matters
For the market, this mainly signals progress at one company: priority review could speed the regulatory path, and cash runway into 2030 reduces the near-term need to raise capital. The final decision rests with the regulator.
market impact
uniQure shares: regulatory progress supports interest in the company
- uniQure shares pressure up — priority review and regulatory progress support investor expectations
tags
instruments
sources
- QURE: AMT-130 enters priority review as confirmatory-trial and launch preparations advance — TradingView, 11 November 2026 at 20:15 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗